Aktuellt
SENASTE
Redeye views Acarix's Q2 as weaker than anticipated, with lower-than-expected revenues. However, the company's ongoing cost-cutting measures positively impacted results, making the EBIT deviation relatively modest. We anticipate making downward revisions to our forecasts and fair value range.
LÄS MER
